Sugi Predict

Sugi Predict / Compounds / SCHEMBL938503

SCHEMBL938503

SCHEMBL938503

CCOC(=O)Cn1cc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.54
▸ UCHL1 P09936 1/20 0.42
▸ JAK1 P23458 12/20 0.39
▸ JAK2 O60674 7/20 0.39
▸ TYK2 P29597 6/20 0.39
▸ JAK3 P52333 3/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ GSK3A P49840 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ DGAT1 O75907 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15298112 0.87 FFAR1 (0.52) FFAR1UCHL1JAK1JAK2TYK2
SCHEMBL4099087 0.86 FFAR1 (0.57) FFAR1UCHL1GSK3AGSK3BSMN1; SMN2
SCHEMBL1712623 0.85 FFAR1 (0.50) FFAR1UCHL1
SCHEMBL23850864 0.84 FFAR1 (0.49) FFAR1UCHL1
SCHEMBL25252237 0.83 FFAR1 (0.48) FFAR1UCHL1
SCHEMBL30806082 0.83 FFAR1 (0.48) FFAR1MAPK1DGAT1
SCHEMBL4251935 0.83 FFAR1 (0.38) FFAR1JAK1JAK2TYK2JAK3
SCHEMBL844227 0.83 FFAR1 (0.60) FFAR1UCHL1JAK1JAK2GSK3A
SCHEMBL12049576 0.82 FFAR1 (0.58) FFAR1UCHL1GSK3AGSK3BDGAT1
SCHEMBL12912195 0.82 FFAR1 (0.61) FFAR1UCHL1GSK3AGSK3BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078094-A1 ANTI-VIRAL COMPOUNDS INFEX THERAPEUTICS LTD (GB) 2026-03-19 — — US disclosed
US-12428421-B2 Pyrimidinones as factor XIA inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-30 — — US disclosed
EP-4587425-A1 ANTI-VIRAL COMPOUNDS Infex Therapeutics Limited (GB) 2025-07-23 — — EP disclosed
WO-2025100970-A1 TNAP INHIBITORY COMPOUND AND USE THEREOF 주식회사 레드엔비아 2025-05-15 — — WO disclosed
WO-2025054339-A1 TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT ARCUS BIOSCIENCES, INC. (US) 2025-03-13 — — WO disclosed
EP-4050005-B1 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE LLC (US) 2024-12-25 — — EP disclosed
US-20240391899-A1 POTENT AND SELECTIVE INHIBITORS OF IRAK4 DANA FARBER CANCER INST INC (US) 2024-11-28 — — US disclosed
US-20240360140-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2024-10-31 — — US disclosed
US-20240360149-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2024-10-31 — — US disclosed
US-12054494-B2 Compound with anticancer activity KYOWA KIRIN CO., LTD. (JP) 2024-08-06 — — US disclosed
WO-2011006567-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GMBH (DE) 2011-01-20 — — WO disclosed
US-20110015178-A1 Amido-Thiophene Compounds and Their Use THE UNIVERSITY OF EDINBURGH (GB) 2011-01-20 — — US disclosed
US-20110015178-A1 Amido-Thiophene Compounds and Their Use THE UNIVERSITY OF EDINBURGH (GB) 2011-01-20 — — US disclosed
US-20110015178-A1 Amido-Thiophene Compounds and Their Use THE UNIVERSITY OF EDINBURGH (GB) 2011-01-20 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
WO-2010059771-A1 SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES OSI PHARMACEUTICALS, INC. (US) 2010-05-27 — — WO disclosed
US-20100063031-A1 KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2010-03-11 — — US disclosed
WO-2009150381-A2 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME SANOFI-AVENTIS (FR) 2009-12-17 — — WO disclosed
WO-2009112845-A1 AMIDO-THIOPHENE COMPOUNDS AND THEIR USE THE UNIVERSITY OF EDINBURGH (GB) 2009-09-17 — — WO disclosed
WO-2008088881-A1 KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2008-07-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD FFAR1 3621/4885UCHL1 4062/4885JAK1 2067/4885
US-20240360140-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 FFAR1 227/4885UCHL1 4589/4885JAK1 2242/4885
US-20240391899-A1 POTENT AND SELECTIVE INHIBITORS OF IRAK4 IRAK4, IRAK1, IRAK2 FFAR1 2365/4885UCHL1 3438/4885JAK1 95/4885
US-12428421-B2 Pyrimidinones as factor XIA inhibitors TFPI, TFPI2, F2 FFAR1 3528/4885UCHL1 4307/4885JAK1 182/4885
US-20100063031-A1 KINASE INHIBITOR COMPOUNDS MAP4K2, MAP3K5, MAP3K15 FFAR1 4647/4885UCHL1 3820/4885JAK1 292/4885
US-20110015178-A1 Amido-Thiophene Compounds and Their Use HSD11B1, HSD11B2, HSD17B1 FFAR1 338/4885UCHL1 3011/4885JAK1 3382/4885
US-12054494-B2 Compound with anticancer activity TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 FFAR1 4554/4885UCHL1 2598/4885JAK1 3040/4885
US-20260078094-A1 ANTI-VIRAL COMPOUNDS CBR1, CBR3, CPN1 FFAR1 1299/4885UCHL1 1534/4885JAK1 2376/4885
US-20240360149-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 FFAR1 4554/4885UCHL1 2598/4885JAK1 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.